This discrimination is in the vast majority of cases possible to achieve by the blood assay of the biomarker human neutrophil lipocalin (HNL), which we showed to be uniquely increased in patients suffering from bacterial infections. This evidence concerns the gene LCN2 and bacterial infectious disease.